Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168), an orally administered, selective C5a receptor inhibitor, could replace oral glucocorticoids without compromising efficacy. In this randomized, placebo-controlled trial, adults with newly diagnosed or relapsing vasculitis received placebo plus prednisone starting at 60 mg daily (control group), avacopan (30 mg, twice daily) plus reduced-dose prednisone (20 mg daily), or avacopan (30 mg, twice daily) without prednisone. All patients received cyclophosphamide or rituximab. The primary efficacy measure was the proportion of patients achieving a ≥50% reduction in Birmingham Vasculitis Activity Score by week 12 and no worsening in any body system. We enrolled 67 patients, 23 in the control and 22 in each of the avacopan groups. Clinical response at week 12 was achieved in 14 of 20 (70.0%) control patients, 19 of 22 (86.4%) patients in the avacopan plus reduced-dose prednisone group (difference from control 16.4%; two-sided 90% confidence limit, -4.3% to 37.1%; P=0.002 for noninferiority), and 17 of 21 (81.0%) patients in the avacopan without prednisone group (difference from control 11.0%; two-sided 90% confidence limit, -11.0% to 32.9%; P=0.01 for noninferiority). Adverse events occurred in 21 of 23 (91%) control patients, 19 of 22 (86%) patients in the avacopan plus reduced-dose prednisone group, and 21 of 22 (96%) patients in the avacopan without prednisone group. In conclusion, C5a receptor inhibition with avacopan was effective in replacing high-dose glucocorticoids in treating vasculitis.

Budai Irgalmasrendi Korhaz Budapest Hungary

ChemoCentryx Inc Mountain View California

Department of Medicine Addenbrooke's Hospital Cambridge United Kingdom;

Department of Nephrology Charles University Prague Czech Republic

Department of Nephrology Linköping University Linköping Sweden; and

Department of Nephrology Rheumatology Diabetology and General Internal Medicine Uniklinik Cologne Cologne Germany

Department of Nephrology University of Birmingham Research Laboratories Queen Elizabeth Hospital Birmingham Edgbaston Birmingham United Kingdom

Department of Renal Medicine Karolinska University Hospital Huddinge Stockholm Sweden

Department of Renal Medicine Manchester Royal Infirmary Manchester United Kingdom

Renal Centre University of Heidelberg Heidelberg Germany

Service de Nephrologie Cliniques Universitaires Saint Luc Brussels Belgium

Zobrazit více v PubMed

Luqmani R, Suppiah R, Edwards CJ, Phillip R, Maskell J, Culliford D, Jayne D, Morishita K, Arden N: Mortality in Wegener’s granulomatosis: A bimodal pattern. Rheumatology (Oxford) 50: 697–702, 2011 PubMed

Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, Jayne D, Harper L; European Vasculitis Study (EUVAS) Group : Early mortality in systemic vasculitis: Relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69: 1036–1043, 2010 PubMed

Jayne D: Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford) 39: 585–595, 2000 PubMed

Koldingsnes W, Nossent H: Predictors of survival and organ damage in Wegener’s granulomatosis. Rheumatology (Oxford) 41: 572–581, 2002 PubMed

Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Lerma-Márquez JL: Overall survival, renal survival and relapse in patients with microscopic polyangiitis: A systematic review of current evidence. Rheumatology (Oxford) 50: 1414–1423, 2011 PubMed

Takala JH, Kautiainen H, Finne P, Leirisalo-Repo M: Wegener’s granulomatosis in Finland in 1981-2000: Risk of dialysis-dependent renal disease. Scand J Rheumatol 40: 283–288, 2011 PubMed

Mohammad AJ, Segelmark M: A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol 41: 1366–1373, 2014 PubMed

Charlier C, Henegar C, Launay O, Pagnoux C, Berezné A, Bienvenu B, Cohen P, Mouthon L, Guillevin L: Risk factors for major infections in Wegener granulomatosis: Analysis of 113 patients. Ann Rheum Dis 68: 658–663, 2009 PubMed

McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH: Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 7: 240–247, 2012 PubMed PMC

Goupil R, Brachemi S, Nadeau-Fredette A-C, Déziel C, Troyanov Y, Lavergne V, Troyanov S: Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 8: 416–423, 2013 PubMed PMC

Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P, Jayne D, Mahr A, Westman K, Luqmani R: Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: Long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford) 54: 471–481, 2015 PubMed

Halbwachs L, Lesavre P: Endothelium-neutrophil interactions in ANCA-associated diseases. J Am Soc Nephrol 23: 1449–1461, 2012 PubMed PMC

Furuta S, Jayne DR: Antineutrophil cytoplasm antibody-associated vasculitis: Recent developments. Kidney Int 84: 244–249, 2013 PubMed

Kettritz R: With complements from ANCA mice. J Am Soc Nephrol 25: 207–209, 2014 PubMed PMC

Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R: C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 20: 289–298, 2009 PubMed PMC

Camous L, Roumenina L, Bigot S, Brachemi S, Frémeaux-Bacchi V, Lesavre P, Halbwachs-Mecarelli L: Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117: 1340–1349, 2011 PubMed

Hammerschmidt DE, Harris PD, Wayland JH, Craddock PR, Jacob HS: Complement-induced granulocyte aggregation in vivo. Am J Pathol 102: 146–150, 1981 PubMed PMC

Tse WY, Nash GB, Hewins P, Savage COS, Adu D: ANCA-induced neutrophil F-actin polymerization: Implications for microvascular inflammation. Kidney Int 67: 130–139, 2005 PubMed

Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA: C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 94: 1147–1155, 1994 PubMed PMC

Schraufstatter IU, Trieu K, Sikora L, Sriramarao P, DiScipio R: Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 169: 2102–2110, 2002 PubMed

Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, Baumgart T, Shugarts S, Lohr L, Dang T, Miao S, Zeng Y, Fan P, Zhang P, Johnson D, Powers J, Jaen J, Charo I, Schall TJ: Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study. PLoS One 11: e0164646, 2016 PubMed PMC

Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold MET, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC: C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25: 225–231, 2014 PubMed PMC

Fauci AS, Katz P, Haynes BF, Wolff SM: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301: 235–238, 1979 PubMed

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group : Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221–232, 2010 PubMed PMC

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Iklé D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group : Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 65: 2441–2449, 2013 PubMed PMC

Kaplan-Pavlovčič S, Cerk K, Kveder R, Lindič J, Vizjak A: Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant 18[Suppl 5]: v5–v7, 2003 PubMed

Stangou M, Asimaki A, Bamichas G, Christidou F, Zoumbaridis N, Natse T, Galanis N, Christaki P, Patakas D, Sombolos K: Factors influencing patient survival and renal function outcome in pulmonary-renal syndrome associated with ANCA (+) vasculitis: A single-center experience. J Nephrol 18: 35–44, 2005 PubMed

Tam FWK, Sanders J-S, George A, Hammad T, Miller C, Dougan T, Cook HT, Kallenberg CG, Gaskin G, Levy JB, Pusey CD: Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant 19: 2761–2768, 2004 PubMed

Tesch GH: MCP-1/CCL2: A new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 294: F697–F701, 2008 PubMed

Wolkow PP, Niewczas MA, Perkins B, Ficociello LH, Lipinski B, Warram JH, Krolewski AS: Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol 19: 789–797, 2008 PubMed PMC

Nadkarni GN, Rao V, Ismail-Beigi F, Fonseca VA, Shah SV, Simonson MS, Cantley L, Devarajan P, Parikh CR, Coca SG: Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD trial. Clin J Am Soc Nephrol 11: 1343–1352, 2016 PubMed PMC

Zheng D, Wolfe M, Cowley BD Jr, Wallace DP, Yamaguchi T, Grantham JJ: Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 14: 2588–2595, 2003 PubMed

Pountain GD, Keogan MT, Hazleman BL, Brown DL: Effects of single dose compared with three days’ prednisolone treatment of healthy volunteers: Contrasting effects on circulating lymphocyte subsets. J Clin Pathol 46: 1089–1092, 1993 PubMed PMC

Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, Lockwood CM: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93: 433–439, 2000 PubMed

Flossmann O, Baslund B, Bruchfeld A, Tervaert JW, Hall C, Heinzel P, Hellmich B, Luqmani RA, Nemoto K, Tesar V, Jayne DRW: Deoxyspergualin in relapsing and refractory Wegener’s granulomatosis. Ann Rheum Dis 68: 1125–1130, 2009 PubMed

Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DRW; European Vasculitis Study Group : Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211–220, 2010 PubMed

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C: EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75: 1583–1594, 2016 PubMed

Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31: 103–115, 1975 PubMed

The role of complement in kidney disease

An update on dıagnosıs and treatment of ANCA assocıated renal vasculıtıs

Complement Inhibition in ANCA-Associated Vasculitis

Emerging Modes of Treatment of IgA Nephropathy